There is no doubt in my mind DCVax-L is an effective treatment against Glioblastoma and it is far superior to any treatment currently available. I also have no doubt that DCVax-L will be incorporated into many combination therapies beyond Keytruda and other combinations that we are currently aware of. LP fortune will materialize after approval and it will be well deserved. Personally I believe after years of watching this company, LP is the perfect CEO to bring DCVax-L to the market successfully. Only a few more weeks until D-Day.
News 
Market Data 
Discover 
AI
